Open Access
Check for updates

International Journal of Medical Science and Dental Health (ISSN: 2454-4191)
Volume 11, Issue 08, August 2025,
Doi: https://doi.org/10.55640/ijmsdh-11-08-02

Recent Advances in Nanotechnology-Driven Analytical Approaches for Medical Diagnostics: A Review

Noor Jamal Mohammed
Department of Basic Science, College of Dentistry, Mustansiriyah University, Baghdad, Iraq

Ali A. Al-fahham
Faculty of Nursing, University of Kufa, Iraq

Corresponding Author: - Ali A. Al-fahham

Received: 18 July 2025, **accepted:** 27 July 2025, **Published Date:** 11 August 2025

Abstract

Nanotechnology has significantly reshaped analytical chemistry by introducing techniques and materials that enhance sensitivity, specificity, and miniaturization of analytical systems. These advances are particularly impactful in medical diagnostics, where early and accurate detection is crucial. As research progresses, further integration of nanomaterials into diagnostic platforms promises continued improvements in assay performance and accessibility, especially in resource-limited settings. It is through nanotechnology and analytical chemistry, that the transformations have occurred in the area of medical diagnostics precipitating from the characteristics of nanoscale materials. Starting from properties such as high surface-to-volume ratio, quantum effects, tunable optical or electrical properties, etc., very sensitive and selective tools for medical diagnostics on ultralow concentrations of biomarkers are being developed. Among them are innovations recently presented here describing gold nanoparticles, quantum dots, carbon nanotubes, graphene, and magnetic nanoparticles-based analytical techniques. The trend biosensors exploited for lateral flow systems in lab-on-a-chip and even wearable sensors cover an application field from early cancer detection to infectious pathogen identification to glucose monitoring with real-time detection up to non-invasive liquid biopsy analysis on circulating tumor biomarkers. Meanwhile, it opens a review window by indicating however nanotechnology integrated together with artificial intelligence and microfluidic systems can result in a laboratory on a chip for personalized healthcare at the patient's bedside. Though issues of reproducibility, cost, and regulatory approval remain, the future convergence of nanotechnology with biomedical diagnostics is extremely promising. This paper further emphasizes the dire need for continued interdisciplinary research and development toward gaining the proposed clinical advantages of nanodiagnostics and making sure about their successful movement from laboratories into real healthcare applications.

Keywords

nanotechnology, analytical approaches, medical diagnostics

Introduction

Medical diagnostics are accurate, available in time, and accessible at wide ranges-that is what characterizes effective health systems. They support clinical decision making, help in the surveillance of infectious as well as noncommunicable diseases and ensure rational distribution of any limited resources available. Persistent diagnostic gaps, particularly within the low- and middle-income regions of the world, delay treatment and increase transmissibility; therefore, healthcare costs become highly inflated. This has made global health policy bodies respond by prioritizing access to high-value in vitro diagnostics as exemplified by WHO's Essential Diagnostics List that offers evidence-based guidance for countries to take up critical tests at different levels of care (WHO, 2023). The parallel technological advance highlights emerging analytical platforms that can be miniaturized integrated and involve rapid readout as real-world needs outside the highly resourced laboratory settings (Lehnert & Gijs, 2024; Tommasone, 2025) .

These needs are most acute in high disease burdens, variable infrastructure, and short point of care (POC) decision windows. The ASSURED (Affordable, Sensitive, Specific, User friendly, Rapid & robust, Equipment free, Deliverable) framework recently evolving into REASSURED by including real time connectivity and easy specimen collection captures the operational performance profile required of diagnostic tools functioning across tertiary hospitals down to community settings (Secchi et al., 2025). Achieving such performance in pathogen rich environments where turnaround time can make a difference on infection control outcomes and supply chains, biosafety as well as operator skill varies significantly is still very challenging (Lehnert & Gijs, 2024) .

Analytical chemistry is the measurement science that provides data for modern diagnostics and translates chemical, biochemical, and biophysical signals into clinically interpretable results. Techniques available include spectroscopic tools (infrared, Raman) capable of molecular fingerprinting; chromatographic separations coupled with mass spectrometry for highly sensitive multiplexed quantification of metabolites, drugs, and protein biomarkers; immunochemical and nucleic acid assays for specific target detection. Increasingly found are miniaturized forms or hybrids between laboratory mainstays and microfluidics and sensor technologies which substantially decrease sample volumes as well as turnaround times yet keep analytical rigor within clinical workflows anywhere from autoimmune to cardiovascular disease testing through infectious disease panels (Kumar et al., 2024; Lehnert & Gijs, 2024).

Reagents on the cold chain, technologists to be trained, and multi-step sample preparation are practically infeasible in decentralized care though conventional bench scale assays. Further, delays in reporting results from sampling can blunt therapeutic impact and impede fast moving outbreak surveillance. Such limitations have driven an acceleration in efforts toward integrating sample handling, analyte recognition, signal transduction, and data reporting into compact formats preserving analytical performance achievable at the levels of the point of care (POC). The architecture for high-end microfluidics is graduated further with sensitive transducers engineered increasingly to support operation characterized as "sample in/answer out"; interfaces structured on the nanoscale are involved increasingly both to enhance efficiency in analyte capture and on detection limit lowering (Secchi et al., 2025; Lehnert & Gijs, 2024; Choi, Choi, & Yoon, 2023).

Nanotechnology has become a key facilitator of this evolution. Nanomaterials—gold and magnetic nanoparticles, quantum dots, metal–organic frameworks, carbon nanotubes, graphene derivatives, polymeric nanocarriers, hybrid nanoshells—surface area to volume, optical and electrical properties tunability, and bioconjugation chemistries available for biomolecule immobilization signal amplification multiplexing facilitate much more sensitive detection. Specifically engineered nanoparticles enhance imaging contrast agents targeted delivery probes enabling theranostics which is the simultaneous detection and treatment of disease (Wang et al., 2024). As an electrode material for biosensors based on electrochemical readout in clinical matrices related carbon nanostructures offer high conductivity with functionalizability in the surface chemistry (Irkham et al., 2023). This is comparable to nano-enabled assays applied for circulating tumor markers where enhancement in transduction will boost early detection ability (Sadeghi et al., 2023) due to incorporation of nanomaterials into the sensing platform as occurs for neurotransmitter sensing platforms developed for monitoring neurological diseases showing cross-disease domain breadth (Choi et al., 2023) .

The meeting of nanomaterials with integrated POC platforms is remodeling the diagnostic design space. Nano enhanced recognition elements within microfluidic cartridges, wearable or implantable sensors connected with the Internet of Medical Things (IoMT), and AI based data analysis are bringing laboratory performance much closer to the bedside and even home settings (Secchi et al., 2025; Irkham et al., 2023). Such infrastructure can be used for telemedicine, provide longitudinal monitoring, and feed a population-based surveillance system whenever available. The broader trends in analytical chemistry that reinforce this trajectory include automation and miniaturization as well as data centric interpretation which are also expected to lower barriers to adoption if issues regarding standardization as well as cost and regulatory alignment are resolved (Tommasone, 2025).

Purpose and scope of this review. Fast-forward, but thematically diffused between the silos of materials science, analytical instrumentation, and clinical translation is the recent wave of nanotechnology driven advances in medical diagnostics related analytical sensitivity which this article reviews with an emphasis on how nanoscale design increases sensitivity, selectivity, multiplexing capability lab and point-of-care readiness. Sensitivity increases under laboratory as well as resource-limited conditions. Evidence on performance leaps and translational bottlenecks extracted from pathogen-, chronic disease biomarker- and cancer diagnostic studies will be integrated. Formulated within global access initiatives such as WHO Essential Diagnostics List Regulatory and Implementation considerations pertaining to data availability will be discussed—here scalability & equity too. Intended herewith is an intersectoral roadmap for researchers developers clinicians relating material choice to analytical readouts thenceforth clinical outcome (WHO, 2023; Wang et al., 2024; Lehnert & Gijs, 2024).

Nanotechnology Analytical Techniques

Nanotechnology is defined as science, engineering, and applications at the nanometer scale—less than 100 nm in most dimensions. Materials developed at such small scales often gain very interesting physical, chemical, and biological properties that may be very different from those found in larger forms of the material. In analytical chemistry, this means new possibilities for sensitivity, selectivity, and miniaturization of chemical and biological detection systems—especially medical diagnostic systems (Salata, 2004).

Analytical chemistry has been availed of with the use of nanotechnology in several ways- nanoparticles, quantum dots, carbon-based nanomaterials, nanoelectromechanical systems (NEMS), and nanosensors. For Examples, some most exploited include gold and silver nanoparticles (AuNPs and AgNPs), carbon nanotubes (CNTs), and graphene. Surface area-to-volume ratio enhancement, tunability of optical and electronic properties, and peculiar catalytic behaviors that can be harnessed toward sensitivity improvement in analytical applications have been described by (Wang et al., 2019).

Colorimetric assays provide easy visual readouts that are directly attributable to the state of aggregation of gold nanoparticles. For example, the presence of certain analytes including protein, DNA, or metal ions make it visible (Draz & Shafiee, 2018). Much in the same way quantum dots do. QDs are actually nanocrystals that belong to semiconductors and their emission strongly depends on their size, providing a convenient path toward multiplexed optical detections within biosensing platforms (Justino et al., 2017).

Another important trend is the use of carbon nanotubes and graphene-based materials for electrochemical sensors. Carbon nanostructures ensure great electrical conductivity, and mechanical strength, as well as large surface area making possible enhancement of electron transfer rates sensitivity in electrochemical sensors. Specific recognition elements (e.g., antibodies or aptamers) functionalized on these nanostructures enable selective detection of disease biomarkers at ultralow concentrations.

Also, magnetic nanoparticles (MNPs) are used mostly those based on iron oxide in sample prep and separation methods within analytical workflows. MNPs allow for fast and easy enrichment or purification of targets from complex biological matrices by means of manipulation of the magnetic field. This has improved pre-analytical diagnostics since background interference is reduced hence accurate detection is attained (Xu et al., 2011). One of the great recent advances has been the development of lab-on-a-chip and microfluidic devices embedded nanomaterials. These platforms present the possibility of sample preparation, reaction, and detection all within a small format. When coupled with nanomaterials they achievable sensitivity heightened even further added with fast analysis time accompanied by reduced reagent consumption—ideal feature sought for diagnostics right at the point-of-care (Choi et al., 2020).

Nanotechnology has also transformed the biosensors. Nanobiosensors are basically defined as the combination of a biological recognition element and a nanostructured transducer which creates measurable signals based on the amount of target analyte present. In clinical diagnostics, this device makes possible the fast detection that is label-free and real-time monitoring for pathogens, cancer biomarkers, and metabolic indicators, which presumes an application in early disease detection and personalized medicine (Zhao et al., 2021).

Analytical Approaches for Medical Diagnostics

The combination of nanotechnology and analytical chemistry has significantly advanced medical diagnostics and provided innovative tools for early, accurate, and non-invasive detection of diseases. Nanoscale materials and systems have those peculiar optical, magnetic, and electrical properties which may be applied to sensitivity, specificity, or speed improvement in diagnostics. Applications range from infectious pathogen and cancer biomarker detections through developments of POC systems up to wearable diagnostic devices. Analytical approaches based on nanotechnology have thus opened new doors towards personalized as well as precision medicine (Wang et al., 2019).

1 .Early disease detection

Early detection is critical toward better treatment of chronic and life-threatening conditions such as cancer, cardiovascular disease, and neurodegenerative disorders. Nanotechnology has within its reach heightened sensitivity toward the identification of biomarkers (molecular indicators of disease) typically present at picomolar or femtomolar concentrations. For example, gold nanoparticles (AuNPs) are extensively used in both colorimetric and surface plasmon resonance (SPR) based detections for proteins and nucleic acids related to cancer (Draz & Shafiee, 2018). After functionalization with antibodies or aptamers, the optical properties of gold nanoparticles change upon binding to target molecules providing visible or measurable signals even at trace levels.

Quantum dots (QDs) refer to another group of nanomaterials applied within fluorescent diagnostic systems because they have size-dependent emission spectra and are very bright. Multiplexing several biomarkers at the same time is an added feature that helps in the identification of disease subtypes or stages. QDs have been used to image prostate-specific antigen (PSA), human epidermal growth factor receptor 2 (HER2), and other cancer markers (Zhao et al., 2021).

2 .Infectious disease diagnostics

The fast spread of infectious diseases has been seen in the COVID-19 pandemic, hence stressing the need for quick, precise, and readily available diagnostic tools. Nanotechnology has greatly enhanced the sensitivity of molecular and immunological detection toward pathogens. Magnetic nanoparticles (MNPs) — mainly those based on iron oxide — are largely applied in magnetic separation and pre-concentration of bacteria, viruses, or nucleic acids from biological fluids. This can be attested by the fact that most assays emanate from an easier interference with complex sample matrices (Xu et al., 2011).

Lateral flow immunoassays (LFIAs) —a major part of rapid diagnostics—have also been advanced further by nanomaterials including gold nanoparticles (AuNPs) and carbon nanoparticles for signal strength and stability. For instance, during the COVID-19 pandemic, nanoparticle-based LFIAs were applied as rapid antigen tests that produced results within minutes thus allowing large-scale screening (Choi et al., 2020). In a related manner, nanoscale biosensors using graphene or carbon nanotubes (CNTs) are being engineered for label-free real-time detection of such viruses as HIV, HBV and Zika with high specificity as well as very low false positive rates. (Justino et al., 2017).

3 .Cancer Diagnostics and Liquid Biopsies

Nanotechnology-based platforms have revolutionized cancer diagnostics by enabling the performance of liquid biopsies on patient plasma samples for circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs). The sensitivity of traditional assays for such rare entities was limited by the volume that could be accommodated. Sensitivity can vastly be improved through nanomaterial-based sensors and microfluidic chips comprising nanostructures, which help in positive enrichment as well as facilitating detection of any one or all possible tumor-derived entities being nano-based electrochemical biosensors using functionalized CNTs or graphene for CTC capture or relevant DNA sequence capture making possible both early diagnosis of cancer and therapeutic efficacy monitoring (Wang et al., 2019).

Also, plasmonic nano rods and nano shells have been applied in SERS surface enhanced Raman scattering for the purpose of bio-molecular fingerprinting. The method is based on SERS-based technology that can pick up molecular vibrations which are characteristic of particular biomarkers allowing very sensitivity as well as label-free detection of targets related to cancer in a noninvasive way (Lee et al., 2022).

4 .Point-of-Care and Wearable Diagnostics

Nano-tech has enabled the reduction in size and complexity of diagnostic platforms, thereby driving point-of-care (POC) devices which can be used for rapid diagnosis at bed-side or remote locations and even at homes. Silver nano-particles, graphene oxide, and MXene based point of care diagnostic devices have been developed for glucose monitoring, cardiac biomarker detection, and infectious disease diagnosis (Koyappayil et al., 2021).

As an example, electrochemical nanosensors as part of integration with wearable devices for the detection of cardiac troponin I-one that provides markers on myocardial infarction-provide results within 10 minutes signaling acute coronary syndrome. The combination will also enable nanoenhanced test strips to provide real-time sharing plus simultaneously analyzable diagnostic results thereby accessibility and health monitoring being enhanced (Choi et al., 2020).

An emerging area is biosensors integrated as patches tattoos or textiles and clothing using flexible nanomaterials. Such devices are capable of continuous monitoring of physiological conditions by sweat, glucose, lactate, or cortisol levels-sensitive signal transmission that brings about improved sensitivity towards even the minutest changes in biochemistry due to nanostructured electrodes. Wearable devices hold a very promising future in the management of chronic diseases, fitness tracking, and even possible applications for mental health monitoring (Zhao et al., 2021).

5 .Neurodegenerative and metabolic diseases

Diagnostics for Alzheimer’s disease, Parkinson’s disease, and diabetes have been transformed by nanotechnology-based platforms. The biomarkers of these diseases are typically found at very low concentrations in either the cerebrospinal fluid, blood, or saliva. Nanobiosensors offer much stronger detection capability with high affinity bioreceptors together with nanoscale signal amplifiers (Lee et al., 2022). For example, Graphene-based field-effect transistor (FET) biosensors, functionalized with aptamers, could sense Alzheimer’s disease-related amyloid β and tau proteins achieve femtomolar sensitivity. In the case of diabetes management nanostructured glucose sensors made out of metal oxides or conductive polymers can continuously detect glucose in real time as well as provide higher accuracy compared to typical test strips. (Justino et al., 2017).

6. Future Trends and Convergence with AI

The coming future of nanotechnology for super-future diagnosis will be based on the combination of Artificial Intelligence (AI) and Machine Learning (ML). First, there will be a large amount of complex data about nanosystems that these tools will be able to analyze. Second, they will identify patterns related to diseases. For instance, AI can analyze images produced through quantum dot-based immunoassays or surface-enhanced Raman spectroscopy (SERS) between healthy and disease states with high accuracy. Another development in nanoDiagnostics combined with Telemedicine and Medical Internet of Things (MIoT) leads to intelligent diagnostic environments capable of remote monitoring, early warning systems, and personal treatment strategies. (Koyappayil et al., 2021).

Conclusion

It is on the basis of optical density that both theoretical and applied optics develop. Ideally, therefore, this review should make evident the great strides that have been made in the field while bringing out gaps of knowledge that exist and need to be filled. Closing these gaps will provide a better understanding of optical density and its applications for new technologies within scientific disciplines. It can also be immensely helpful in increasing assay sensitivity as well as making assays and sensor technologies more reliable with optical density determination being an important parameter. New material and methodology for determining optical density open interesting perspectives for investigation, which would lead toward general enhancement for efficiency in laboratory biochemical analyses. The importance of optical density has been demonstrated most recently bringing about useful applications from enzymatic assays in biochemical research and clinical diagnostics. By merging new tech and getting the underlying workings better, the area can keep changing, making a path for more effective, keen, and targeted tests in many uses. Ongoing digging into the info holes noted in this look will make the handiness of optical density in enzyme tests better and help push forward improvements in ways to diagnose.

References

1. Choi, H. K., Choi, J.-H., & Yoon, J. (2023). *An updated review on electrochemical nanobiosensors for neurotransmitter detection.* Biosensors, 13(9), 892. https://doi.org/10.3390/bios13090892
2. Choi, J. R., Yong, K. W., Choi, J. Y., & Cowie, A. C. (2020). Emerging point-of-care technologies for food safety analysis. *Sensors*, 20(8), 2584. https://doi.org/10.3390/s20092584
3. Draz, M. S., & Shafiee, H. (2018). Applications of gold nanoparticles in virus detection. *Theranostics*, 8(7), 1985–2017. https://doi.org/10.7150/thno.23856
4. Irkham, I., et al. (2023). *Smart graphene-based electrochemical nanobiosensor for clinical diagnosis: Review.* Sensors, 23(4), 2240. https://doi.org/10.3390/s23042240
5. Justino, C. I., Rocha-Santos, T. A., & Duarte, A. C. (2017). Advances in point-of-care technologies with biosensors based on carbon nanotubes. *TrAC Trends in Analytical Chemistry*, 89, 1–18. https://doi.org/10.1016/j.trac.2017.01.001
6. Koyappayil, A., Yadav, S., & Sharma, R. (2021). Integration of nanotechnology and artificial intelligence for precision diagnostics. *Biosensors and Bioelectronics*, 190, 113438. https://doi.org/10.1016/j.bios.2021.113438
7. Kumar, A. S., et al. (2024). *Microfluidics as diagnostic tools.* Clinica Chimica Acta, 117841. https://doi.org/10.1016/j.cca.2024.117841
8. Lee, M., Kim, D., & Park, C. (2022). Recent advances in graphene-based field-effect transistor biosensors for biomedical applications. *Biosensors*, 12(6), 443. https://doi.org/10.3390/bios12060443
9. Lehnert, T., & Gijs, M. A. M. (2024). *Microfluidic systems for infectious disease diagnostics.* Lab on a Chip, 24, 1441–1493. https://doi.org/10.1039/D4LC00117F
10. Sadeghi, M., Sadeghi, S., Naghib, S. M., & Garshasbi, H. R. (2023). *A comprehensive review on electrochemical nano biosensors for precise detection of blood-based oncomarkers in breast cancer.* Biosensors, 13(4), 481. https://doi.org/10.3390/bios13040481
11. Salata, O. V. (2004). Applications of nanoparticles in biology and medicine. *Journal of Nanobiotechnology*, 2(1), 3. https://doi.org/10.1186/1477-3155-2-3
12. Secchi, V., Armanni, A., Barbieri, L., et al. (2025). *Advanced techniques and nanotechnologies for point-of-care testing.* Frontiers in Nanotechnology, 6, 1465429. https://doi.org/10.3389/fnano.2024.1465429
13. Tommasone, S. (2025, February 14). *What role does analytical chemistry play in medicine?* AZoLifeSciences. (Editorial overview article).
14. Wang, B., Hu, S., Teng, Y., et al. (2024). *Current advance of nanotechnology in diagnosis and treatment for malignant tumors.* Signal Transduction and Targeted Therapy, 9, 200. https://doi.org/10.1038/s41392-024-01889-y
15. Wang, Y., Yang, F., Shen, H., & Wang, M. (2019). Nanomaterials as signal amplification elements in aptamer-based electrochemical biosensors. *Critical Reviews in Analytical Chemistry*, 49(1), 1–12. https://doi.org/10.1080/10408347.2017.1399211
16. World Health Organization. (2023, October 19). *WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests; personal use glucose meters.* Author.
17. Xu, H., Aguilar, Z. P., Yang, L., Kuang, M., Duan, H., Xiong, Y., & Wei, H. (2011). Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. *Biomaterials*, 32(36), 9758–9765. https://doi.org/10.1016/j.biomaterials.2011.08.085
18. Zhao, X., Zhang, Y., & Wei, H. (2021). A review of nanobiosensors for detection of foodborne pathogens. *Sensors*, 21(7), 2142. https://doi.org/10.3390/s21072142